Supporting you in the fight against COVID-19

Covid 19 Response

At Fresenius Kabi, our mission is caring for life and our purpose is to put lifesaving medicines in the hands of people who care for patients and to find solutions to the challenges they face. Never has this been more important than today. Even though right now we must all stand a few feet further apart, we are proud to work shoulder to shoulder with you and to do everything we can to support the heroic and selfless actions on the front lines of COVID-19 patient care.

 

As a leading manufacturer and supplier of U.S. sterile injectables – medicines being used every day to treat the respiratory conditions and other complications that have defined this pandemic ­– we are focused on delivering the support our customers need today, and just as important, we are preparing for what may come next. That’s why we’re ramping up production of critical injectable medicines across our expanding U.S. manufacturing network. It’s why we’re deploying essential drugs and devices to distribution centers closer to hospitals across the country. And why we’re committed to assuring we keep one another safe — in our facilities, in our homes, and in our communities. 


Here are just some of the ways our team is working around the clock to assure you can provide excellent care for your patients.

 

 

US Manufacturing

Reliability and Continuity of Supply

Over the last three years, we have invested more than $800 million in three U.S.-based manufacturing plants and another $100 million in three new distribution centers throughout the U.S. This capacity expansion helps us more rapidly adapt to shifting customer needs.

80 percent US

80 percent of our pharmaceutical products are filled and packaged at our three U.S. production sites. This can help us shorten the time required to respond to market demand fluctuations, especially during these critical emergency situations.

In 2019, Fresenius Kabi secured continuity of supply agreements with Group Purchasing Organizations and during the pandemic added several new products to these agreements. 

25 percent increase

In 2020, Fresenius Kabi reprioritized pharmaceutical production to focus on COVID-19-related critical drugs such as sedatives, pain medications, antibiotics, paralytics, anti-coagulants and anti-emetics. We’ve increased supply output for these products by 25 percent compared to historical levels. 

Fresenius Kabi offers a broad portfolio of injectable medicines to support COVID-19 patients. We deliver more than 400 million units of generic injectable medicines in total to U.S. hospitals and clinics each year.

We shipped many products direct from our Fresenius Kabi warehouses to our customers for emergency patient need situations during the initial COVID-19 surge in March and April 2020.  

We were granted Emergency Use Authorization from the FDA for a sedative medication to be used in Intensive Care Units.

Elevated Manufacturing

Assuring Readiness 

We will continue to manufacture COVID-19-related critical products at elevated levels in preparation for a potential second wave of, or a sustained incidence of, COVID-19 in the U.S. 

We have leveraged the breadth of our global purchasing network to increase and expedite the purchase of raw materials for COVID-19-related critical medicines. 

We continue meticulous, collaborative planning so we can anticipate and prepare to respond to emerging needs such as geographic hot spots, spikes and critical care emergencies.

Advancing Therapies

Advancing Therapies and Care

Our blood separation technologies are being used to collect convalescent plasma to help treat coronavirus patients today, as well as to support those working to develop and manufacture future treatments for these patients. 

We prioritized the production of other critical drugs required for non-COVID-19 patient care and we are ready to serve our customers as elective procedures resume.

We are here to support our customers during and after the COVID-19 pandemic through our leadership efforts in parenteral nutrition, opioid stewardship and patient safety with ready-to-administer (RTA) injectable drug delivery solutions.
 

Daily contact

Getting the Right Products Where They’re Needed

We are working closely with the U.S. Department of Health and Human Services (HHS), the U.S. Food and Drug Administration (FDA) Office of Drug Shortages, the U.S. Federal Emergency Management Agency (FEMA) and the U.S. Drug Enforcement Agency (DEA) to be prepared to address hot spots and spikes.

Fresenius Kabi is working with the U.S. Department of Health and Human Services (HHS) and the HHS Assistant Secretary for Preparedness and Response (ASPR) to increase supplies and availability of critically needed ICU medications held in the Strategic National Stockpile (SNS) as cases of COVID-19 continue and new hot spots emerge.

We remain in daily contact with pharmaceutical wholesalers, hospital purchasing groups and multiple professional associations like the American Society of Health-System Pharmacists and the American Society of Anesthesiologists to facilitate support for critically ill patients.

Light bulb

Helping You Make Informed Decisions, Quickly